Navigation Links
ThromboGenics N.V.: Business Update
Date:11/6/2008

enics announced that a group of

private investors based in Belgium had together acquired an 8% stake in

the Company. This stake was purchased from Biggar Limited, a charitable

foundation that is ThromboGenics' largest single shareholder. Biggar

now holds a 9.8% stake in ThromboGenics, and has informed the Company

that it intends to remain an important shareholder in ThromboGenics for

the long term.

- ThromboGenics shares entered the Bel Mid Index on 1 October

2008, following the quarterly review of the Belgian indices by

Euronext. The elevation of ThromboGenics to the Bel Mid Index reflects

the significant progress that the Company has made since its IPO in

2006.

Corporate Update

- On 1 September, Patrik De Haes, MD, formerly the Company's

Chief Operating Officer, was appointed to succeed Professor Desire

Collen as the Company's new Chief Executive Officer. Dr. De Haes will

be proposed to become a member of the Board of Directors of

ThromboGenics at the next General Meeting. In the meantime, he will be

invited to participate in Board meetings.

ThromboGenics will continue to benefit from Professor Collen's significant scientific and drug discovery knowledge. Professor Collen will remain Chairman of ThromboGenics' Board of Directors.

Pipeline Update

Microplasmin in Eye Disease

ThromboGenics is working to finalise its Phase III clinical trial program for microplasmin in the treatment of back of the eye disease, following a successful End of Phase II meeting with the FDA. The initial indication planned for the program is the nonsurgical resolution of vitreomacular adhesion. Two placebo controlled trials are planned, one in the U.S. and one combined European and North American trial. Together it is anticipated that the two trials will recruit a total of approximately 640 patients, with the first trial ex
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. ThromboGenics Announces Half Year Results 2008
2. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
3. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
4. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
5. ThromboGenics N.V. - Business Update
6. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
7. ThromboGenics Announces 2007 Full Year Results
8. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
9. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
10. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
11. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/13/2014)... According to population studies: “North Carolina ... and 2030." If a population explosion like that actually ... state in the country. , To that end, North ... of North Carolina Forum on December 16th to ask ... necessary infrastructure in place? Enough clean water? And will ...
(Date:12/13/2014)... 2014  Vermillion, Inc. (NasdaqCM: VRML), a bio-analytical solutions company ... Veronica G. H. Jordan , Ph.D., and ... Directors, bringing the total number of directors to eight, ... Jim LaFrance , Chairman, President, and Chief Executive Officer ... the appointments of Veronica and David to our board ...
(Date:12/13/2014)... 12, 2014  Vaccinex Inc., a clinical-stage ... development of therapeutic monoclonal antibodies to treat ... of a manuscript entitled "SEMA4D compromises blood–brain ... neurodegenerative disease" in the January 2015 issue ... publication highlights an important role for antibodies ...
(Date:12/12/2014)... Schlieren, Switzerland (PRWEB) December 11, 2014 ... for toxicity and efficacy testing, announced today that data ... InSphero’s 3D liver microtissues as a more predictive model ... Findings presented at the 2nd Annual Functional Analysis ... project to assess the response of InSphero’s 3D ...
Breaking Biology Technology:North Carolina Chamber of Commerce: Asking Questions & Gathering Answers with a Futurist 2Vermillion Strengthens Board of Directors with Appointments of Veronica Jordan, Ph.D., and David Schreiber 2Vermillion Strengthens Board of Directors with Appointments of Veronica Jordan, Ph.D., and David Schreiber 3Vaccinex announces publication of preclinical studies with an anti-SEMA4D antibody in animal models of neuroinflammatory and demyelinating disease 2Enhanced Sensitivity of InSphero 3D Liver Microtissues Highlighted at Annual Screening Congress 2Enhanced Sensitivity of InSphero 3D Liver Microtissues Highlighted at Annual Screening Congress 3
...  Ambit Biosciences today announced that Michael A. Martino, Ambit,s president ... company and an update about its clinical development programs, including ... in New York City. , 14th Annual BIO ... on Monday, February 13, 2012 , Leerink Swann ...
... 9, 2012  Micross Components, a leading global provider ... to announce its participation in the "Drive for ... Electronics. Included as a "pit stop" during the ... selected because of its role in powering innovation ...
... Inc. (NYSE Amex: CUR ) announces that President ... BIO CEO & Investor Conference 2012 in New York City ... present a business overview, and an update on the company,s ... divisions. (Logo:  http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO ) ...
Cached Biology Technology:Ambit Biosciences to Present at Two Upcoming Investor Conferences 2Micross Components Hosts Stop on "Drive for Innovation" Tour 2Neuralstem President and CEO to Present at BIO CEO & Investor Conference 2012 2Neuralstem President and CEO to Present at BIO CEO & Investor Conference 2012 3
(Date:12/10/2014)... NEW YORK , Dec. 8, 2014 You,ve ... online banking account but can,t remember your password, site key ... birthday? Who was your first grade teacher? ... launches the app that will finally put an ... PINs – 1U TM . 1U leverages a ...
(Date:12/10/2014)... 9, 2014     ...   Jifflenow, a ... solutions for business-to-business (B2B) events, today announced a ... mobile near-field communication (NFC), Bluetooth low energy (BLE), ... http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will integrate its ...
(Date:12/3/2014)... , Dec. 2, 2014 As part ... readers, Inception Technologies is pleased to announce the release ... for customers to collect the workforce data that they ... that have been left by existing readers. Many such ... interface, connectivity and modern technology. Older models force users ...
Breaking Biology News(10 mins):The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Inception Technologies to Release New Biometric Reader 2
... purifiers that produce even small quantities of ozone may ... same time as household cleaning products, scientists at UC ... reacts in the air with unsaturated volatile organic compounds ... that gives them a lemon fragrance ?to create additional ...
... will hold a meeting in Toronto to gather information on ... further introductions of nonindigenous aquatic species into the lakes by ... will comment on the strengths and weaknesses of various options ... DETAILS: 9 a.m. to 5:30 p.m. on May 7 ...
... a single dose, blocks the brain’s ability to strengthen connections ... in Nature. , The findings, uncovered in the laboratory of ... addiction in the brain. The research also supports a provocative ... memory. , "We’ve added a new piece to the ...
Cached Biology News:In presence of fragrant cleaning products, air purifiers that emit ozone can dirty the air 2Morphine makes lasting -- and surprising -- change in the brain 2
Mouse monoclonal [2A4] to Cytokeratin 8 + 18 + 19 ( Abpromise for all tested applications). Antigen: Cytokeratins isolated from cultured pig kidney epithelial cells. Entrez GeneID: 3856 S...
Feline Rhinotracheitis Virus...
Rabbit anti-NFkB p105/p50 (Ser529) Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
ABCA1 Immunogen: Mouse ABCA1-expressing HeLa stable transfectants. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: